CLOs on the Move

Bioanalytical Systems

www.basinc.com

 
BASi is a drug discovery and development services company with the energy and expertise to help you with your drug development project. We provide world-class research to the global pharmaceutical industry. Our services include Preclinical Toxicology, Early In Vivo PK, Bioanalysis and a full range of pharmaceutical analysis services. BASi also manufactures innovative scientific instruments including the Culex® Automated In Vivo Sampling System which can collect blood, bile, microdialysates, activity behavior, telemetry data and more from awake, freely-moving subjects. We are known for our scientific expertise, responsiveness to clients, exemplary regulatory record, and helping our clients meet key milestones on ...
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million
  • www.basinc.com
  • 2701 Kent Ave
    West Lafayette, IN USA 47906
  • Phone: 765.463.4527

Executives

Name Title Contact Details

Similar Companies

Avanti Polar Lipids

Avanti Polar Lipids is a Alabaster, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GlobalMedia Group

GlobalMedia Group, LLC is a Scottsdale, AZ-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Sunnycrest Chalet

Sunnycrest Chalet is a Fullerton, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AbboMax

AbboMax is a San Jose, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Orbus Therapeutics

Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.